| Market Capitalization (Millions $) |
- |
| Shares
Outstanding (Millions) |
71 |
| Employees |
- |
| Revenues (TTM) (Millions $) |
21 |
| Net Income (TTM) (Millions $) |
-37 |
| Cash Flow (TTM) (Millions $) |
-46 |
| Capital Exp. (TTM) (Millions $) |
3 |
Business Description
Genocea Biosciences Inc is a biopharmaceutical company that focuses on developing T cell-directed vaccines and immunotherapies to treat diseases caused by pathogens or cancer. The company's proprietary technology platform, ATLAS, enables the identification and prioritization of potentially effective T cell antigens.
Genocea's lead product candidate is GEN-003, a therapeutic vaccine being developed for the treatment of genital herpes. The vaccine aims to stimulate the body's immune response to fight against the virus, potentially reducing the frequency and severity of outbreaks.
Additionally, the company has a pipeline of immunotherapies targeting a range of infectious diseases and cancer. Genocea utilizes its expertise in antigen identification and selection to develop personalized cancer immunotherapies, known as neoantigen vaccines.
Overall, Genocea Biosciences Inc is dedicated to advancing innovative immunotherapies and vaccines to address unmet medical needs and improve patient outcomes.
Company Address: 100 Acorn Park Drive Cambridge 2140 MA
Company Phone Number: 876-8191 Stock Exchange / Ticker: NASDAQ GNCA
|
%